RHS Expands Management Expertise

Aug 18, 2017 -


  • Alwin Hui appointed to sales and marketing executive role

RHS Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce it has appointed Alwin Hui to the newly created position of Chief Commercial Officer.  Alwin was most recently the Global Sales and Marketing Director for Genea BioMedx, a business unit of Sydney-based IVF provider Genea, which commercialises innovative IVF instrumentation, consumables, culture medium and software. 

In his role with RHS, Alwin has responsibility for sales and marketing of DOPlify™, EmbryoCellect® and PG-Seq™ for IVF and non-IVF markets.  RHS CEO Dr Michelle Fraser commented that “It is a pleasure to be welcoming Alwin to the RHS team as we build a sales and marketing core for the Company.  Our products have reached the stage where they have been technically proven and are receiving positive market response.  The IVF market is one of the most integrated clinical applications of single cell genomic analysis. Bringing an experienced executive into this role with a track record in the IVF market is an ideal fit.  Having dedicated sales and marketing resources will also accelerate our efforts in accessing other single cell genomics markets, particularly in liquid biopsy.  We look forward to continued growth of our opportunities and revenues as the Company scales up capabilities with dedicated resources.”

Read more at ASX

< Back to all news